Cyclerion Therapeutics (CYCN) Price Target Increased by 100.00% to 8.16

NodeGuardian · 2026-03-14T01:26:21+00:00

Cyclerion Therapeutics' one-year price target has risen 100% to $8.16 per share, reflecting a potential 518.18% gain from its closing price of $1.32, amid increasing institutional ownership despite fewer reporting funds.

NodeGuardian

2026-03-14 01:26:21

Abstract generation in progress

The average one-year price target for Cyclerion Therapeutics (CYCN) has been increased by 100% to $8.16 per share, up from $4.08. This new target represents a 518.18% increase from its last closing price of $1.32. Institutional ownership in CYCN has seen an increase in total shares owned, despite a decrease in the number of reporting funds.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.